Literature DB >> 31635827

Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy.

Sho Kiritani1, Junichi Arita1, Masaru Matsumura1, Yujiro Nishioka1, Hiroki Kudo1, Akihiko Ichida1, Takeaki Ishizawa1, Nobuhisa Akamatsu1, Junichi Kaneko1, Kiyoshi Hasegawa2.   

Abstract

BACKGROUND: The value of repeat hepatectomy for intrahepatic recurrence after curative resection of neuroendocrine liver metastasis (NELM) remains unclear. The aim of this retrospective cohort study was to determine the significance of repeat hepatectomy for recurrent NELM.
METHODS: Patients who underwent hepatectomy for NELM between 1994 and 2016 were identified. The indications for a first hepatectomy were adequate liver remnant volume and no extrahepatic metastasis. The diagnosis of recurrent NELM was based on radiographic examinations. The indications for a repeat hepatectomy were the same as those for the first hepatectomy. Clinicopathologic factors, short-term survival, and long-term survival were investigated using clinical records.
RESULTS: Forty-four patients enrolled in this study. Thirty-three patients among them underwent a curative hepatectomy, and 28 of them developed recurrence. Of them, 16 patients underwent a repeat hepatectomy. The overall survival of the repeat hepatectomy cohort (n = 16) was significantly better than that of the no repeat hepatectomy cohort (n = 12) (P < .001). The progression free survival after the first hepatectomy (n = 44) and that after repeat hepatectomy (n = 16) were similar (P = .546). No significant difference was seen between the frequency of major complications (Clavien-Dindo score ≥ 3a) after the first and repeat hepatectomy (P = .279). No repeat hepatectomy (hazard ratio [HR] 5.0, P = .036) was identified as an independent predictive factor of a poor outcome among the recurrent cohort, along with the presence of multiple nodules (HR 26.2, P = .008) and a CA19-9 level ≥40 U/mL (HR 11.2, P = .012).
CONCLUSIONS: A repeat hepatectomy is feasible in selected patients with recurrent NELM.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31635827     DOI: 10.1016/j.surg.2019.08.020

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

Review 1.  [Liver metastases of neuroendocrine tumors].

Authors:  S Nadalin; M Peters; A Königsrainer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-17

2.  Management of neuroendocrine liver metastasis: Searching for new prognostic factor and appraising repeat hepatectomy.

Authors:  Junichi Arita; Sho Kiritani; Kiyoshi Hasegawa
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

3.  Case Report: Pancreatic Neuroendocrine Tumor With Liver Metastasis and Portal Vein Thrombosis.

Authors:  Yulong Tian; Xingshun Qi; Afaf Aljbri; Ke Xu; Hongshan Zhong
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.